“If you only have a limited number of doses of an experimental medicine, what do you do with that? Do you make it available for expanded access or do you gain more data for your ultimate drug approval?”– Kenneth Moch.
Kenneth I. Moch is the former President & CEO of Chimerix, Inc., an antiviral therapeutics company. In March/ April 2014, Ken guided Chimerix through a media firestorm around compassionate use of an early-stage developmental drug. Andrea Charles, Editor for Pharma IQ, speaks to Ken one year on about the leadership challenges and ethical dilemmas surrounding compassionate use and expanded access programs in drug development, lessons learnt and opportunities for the future.
|
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |